Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Bimatoprost (lashes) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Prescription topical. Bimatoprost 0.03% is applied once daily as a thin line to the skin of the UPPER eyelid margin at the lash base (not to the lower lid, and avoid getting it in the eye), using a fresh applicator per eye. Continuous use is needed to maintain results. Use under a clinician, especially if you have glaucoma or take prostaglandin eye drops. There is no oral or systemic use. This library does not provide an ingestion protocol.
evening
Bimatoprost 0.03% solution (Latisse) with single-use applicators, under a clinician
Topical cosmetic only. Kojic acid is typically used at roughly 1-2% in leave-on serums or creams (or as the more stable kojic acid dipalmitate), applied to areas of hyperpigmentation once or twice daily, often alongside other brighteners and daily sunscreen. There is no oral, injectable, or systemic dose — it is not ingested. This library does not provide an ingestion protocol.
any
Leave-on topical serum or cream (≈1-2% kojic acid, or kojic acid dipalmitate)
Throughout
8-16 weeks
2-6 months after stopping
Weeks to months
Throughout
8-12 weeks
Throughout
1-12 months
Long-term safety and efficacy of bimatoprost solution 0.03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial.
Br J Dermatol (2015) · Rct
1-year double-masked RCT: composite primary endpoint (Global Eyelash Assessment + satisfaction) met for bimatoprost vs vehicle in idiopathic (40.2% vs 6.8%) and post-chemotherapy (37.5% vs 18.2%) hypotrichosis
Bimatoprost for eyelash growth in Japanese subjects: two multicenter controlled studies.
Aesthetic Plast Surg (2014) · Rct · n=209
Two double-masked vehicle-controlled RCTs (n=209: 173 idiopathic, 36 chemotherapy-induced) in Japanese subjects
The efficacy of topical prostaglandin analogs for hair loss: A systematic review and meta-analysis.
Front Med (Lausanne) (2023) · Meta analysis
Meta-analysis of six placebo-controlled RCTs of topical prostaglandin analogs (incl. bimatoprost) for hair growth (lashes, brows, scalp)
Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid.
Dermatol Surg (1999) · Rct · n=40
Split-face randomized design in 40 women with epidermal melasma: 2% kojic acid added to a 10% glycolic acid + 2% hydroquinone base vs the base alone
Efficacy and safety of topical agents in the treatment of melasma: What's evidence? A systematic review and meta-analysis.
J Cosmet Dermatol (2023) · Meta analysis
Pooled 45 efficacy studies (2359 patients) of topical melasma treatments using MASI standardised mean differences
Kojic Acid vis-a-vis its Combinations with Hydroquinone and Betamethasone Valerate in Melasma: A Randomized, Single Blind, Comparative Study.
Indian J Dermatol (2013) · Rct · n=80
80 melasma patients randomized over 12 weeks to kojic acid 1% alone, kojic acid + hydroquinone 2%, kojic acid + betamethasone, or all three (MASI-assessed)
Bimatoprost (lashes) has a higher evidence score (8/10 vs 6/10) and wins in 2 of 3 categories.
No known interactions between Bimatoprost (lashes) and Kojic Acid have been documented in our database. However, always consult a healthcare provider before combining supplements.